APLM
Apollomics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.50
−1.84%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.7M | 8.5M | 198.0K | 821.0K | 323.0K |
| Cost of Revenue | — | 255.0K | — | — | — |
| Gross Profit | 8.7M | 8.2M | 198.0K | 821.0K | 323.0K |
| Operating Expenses | |||||
| R&D Expense | 30.1M | 5.5M | 24.6M | 34.2M | 35.5M |
| SG&A Expense | 30.2M | 12.4M | 17.8M | 20.6M | 9.9M |
| General & Admin Expense | 32.3M | — | 17.8M | 20.6M | 9.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (255.0K) | — | — | — |
| Total Operating Expenses | 60.3M | 17.7M | 42.3M | 54.8M | 45.4M |
| Cost and Expenses | 60.3M | 18.0M | 42.3M | 54.8M | 45.4M |
| Operating Income (EBIT) | (51.6M) | (9.5M) | (42.1M) | (54.0M) | (45.1M) |
| Non-Operating | |||||
| Interest Income | 301.0K | 152.0K | 480.0K | 753.0K | 431.0K |
| Interest Expense | 65.0K | 65.0K | 179.0K | 150.0K | 93.0K |
| Net Interest Income | 236.0K | 87.0K | 301.0K | 603.0K | 338.0K |
| Other Non-Op Income/Expense | (12.9M) | (1.5M) | (11.5M) | (118.6M) | (195.7M) |
| Non-Operating Income (excl Interest) | 883.0K | — | (1.0M) | (464.0K) | (1.0M) |
| EBT (Pre-Tax Income) | (64.5M) | (10.9M) | (53.6M) | (172.6M) | (240.8M) |
| Income Tax Expense | 262.0K | 3.0K | 259.0K | 10.0K | 1.0K |
| Bottom Line | |||||
| Net Income | (64.8M) | (10.9M) | (53.9M) | (172.6M) | (240.8M) |
| Earnings from Cont. Ops | (64.8M) | (10.9M) | (53.9M) | (172.6M) | (240.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (64.8M) | (10.9M) | (53.9M) | (172.6M) | (240.8M) |
| Per Share | |||||
| Basic EPS | ($62.05) | ($7.57) | ($52.80) | ($231.99) | ($61.60) |
| Diluted EPS | ($62.49) | ($7.57) | ($52.80) | ($231.99) | ($61.60) |
| Revenue Per Share | $20.66 | $5.88 | $0.21 | $1.10 | $0.37 |
| Shares | |||||
| Basic Shares Outstanding | 421000 | 1.4M | 926474 | 743970 | 867958 |
| Diluted Shares Outstanding | 421000 | 1.4M | 926474 | 743970 | 867958 |
| Profitability Metrics | |||||
| EBITDA | (50.5M) | (9.2M) | (41.1M) | (53.4M) | (43.9M) |
| D&A | 72.0K | 255.0K | 72.0K | 103.0K | 182.0K |
| EBIT | (50.6M) | (9.5M) | (41.1M) | (53.5M) | (44.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025